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Several serotypes of Escherichia coli produce protein
toxins closely related to Shiga toxin (Stx) from Shigella
dysenteriae serotype 1. These Stx-producing E. coli
cause outbreaks of hemorrhagic colitis and hemolytic
uremic syndrome in humans, with the latter being more
likely if the E. coli produce Stx2 than if they only pro-
duce Stx1. To investigate the differences among the
Stxs, which are all AB5 toxins, the crystal structure of
Stx2 from E. coli O157:H7 was determined at 1.8-Å reso-
lution and compared with the known structure of Stx.
Our major finding was that, in contrast to Stx, the active
site of the A-subunit of Stx2 is accessible in the holo-
toxin, and a molecule of formic acid and a water mole-
cule mimic the binding of the adenine base of the sub-
strate. Further, the A-subunit adopts a different
orientation with respect to the B-subunits in Stx2 than
in Stx, due to interactions between the carboxyl termini
of the B-subunits and neighboring regions of the A-sub-
unit. Of the three types of receptor-binding sites in the
B-pentamer, one has a different conformation in Stx2
than in Stx, and the carboxyl terminus of the A-subunit
binds at another. Any of these structural differences
might result in different mechanisms of action of the
two toxins and the development of hemolytic uremic
syndrome upon exposure to Stx2.
Several serotypes of Escherichia coli produce one or more
protein toxins that are closely related to Stx from Shigella
dysenteriae serotype 1 (1). Stx from S. dysenteriae was first
identified by Kiyoshi Shiga for whom these toxins are named
(2). Collectively these E. coli are known as Stx-producing E. coli
(STEC).1 E. coli O157:H7 is the STEC responsible for many
outbreaks of hemorrhagic colitis or bloody diarrhea in the U.S.,
Canada, and Japan. In some patients the prodrome of hemor-
rhagic colitis may progress to the hemolytic uremic syndrome,
which culminates in kidney failure. Two types of Stx may be
produced by STEC, Stx1 and/or Stx2. The Stx types all have an
AB5 structure, in which a single A-subunit is associated with
five B-subunits. The A-subunit embodies the N-glycosidase
catalytic activity; it acts by removing a specific adenine base
from the 28 S rRNA of the 60 S ribosomal subunit within
infected cells. Because this adenine base is on a loop of rRNA
that is important for elongation factor binding, the toxin is able
to shut down protein synthesis in a targeted cell. The A-subunit
of Stx1 is nearly identical to the A-subunit of Stx; it differs only
by the change of a single serine residue at position 45 to a
threonine (Table I). In contrast, the amino acid sequence iden-
tity between the A-subunits of Stx1 and Stx2 is only 55%. The
B-pentamer of the Stxs contains the binding sites for glycolip-
ids that are located on the surface of target cells, and thus
mediates entry of the catalytic A-subunit into cells. Although
the Stx1 group is homogeneous, the Stx2 group has a number
of variants. Variants of Stx2 include Stx2c, Stx2d, Stx2d-acti-
vable, Stx2e, and Stx2f. Only the Stx2c variant of Stx2 has
been found in the O157 serotypes. The Stx2 variants are dis-
tinguished by a difference in biological activity, immunological
reactivity, or the receptor to which they bind. Stx1, Stx2, and
the Stx2 variants bind preferentially to the glycosphingo-
lipid globotriaosylceramide (Gal1– 4Gal1– 4glucosyl cer-
amide, Gb3) with the exception of Stx2e, which binds preferen-
tially to globotetraosylceramide (GalNAc1–3Gal1–4Gal1–
4glucosyl ceramide). These different binding properties lead to
the ability of the toxin to target different cells.
The molecular structure of the Stx1 B-pentamer alone was
first determined using x-ray crystallography. This structure
showed five B-subunits in a pentameric arrangement (3), sim-
ilar to the arrangement of the B-subunits of the heat-labile
enterotoxin (4). In heat-labile enterotoxin the five B-subunits
surround a pore through which the carboxyl-terminal residues
of the A-subunit traverse. When the structure of Stx was
solved, the carboxyl-terminal tail of the A-subunit was found to
be surrounded by its five B-subunits like heat-labile entero-
toxin, whereas the remainder of the A-subunit lay on one side
of the B-pentamer (5). The determinations of the structures of
the Stx1 B-subunits and of their mutated forms, alone and in
complex with sugars, have led to a better understanding of the
binding properties of the B-pentamer (6–8) and have served as
templates in the design of inhibitors to cell binding (9, 10).
The A-subunit of the Stxs can be proteolytically cleaved at a
susceptible site (11), but the two portions, A1 (27.5 kDa) and A2
(4.5 kDa), remain covalently associated through a disulfide
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bond until the two cysteine residues are reduced. The disulfide
bond is between Cys-A241 and Cys-A260 in Stx2 (Table I). The
amino acid residues forming the N-glycosidase catalytic site
are on A1. The active site residues were initially predicted from
the amino acid sequence similarity between A1 and the cata-
lytic subunit of the toxin ricin found in castor beans (Table I)
(12) and subsequently confirmed with genetic studies (summa-
rized by Melton-Celsa and O’Brien (13)). The catalytic mecha-
nism of ricin has been investigated in detail: the adenine base
binds between two tyrosine side chains, Tyr-80 and Tyr-123,
whereas Arg-180 is thought to act as an acid and Glu-177
either acts as a base to activate a water molecule or stabilizes
the transition state (summarized in Ref. 14). In the structure of
Stx, the disulfide bond connecting A1 and A2 is located near the
residues that form the N-glycosidase active site; a methionine
residue, only one residue away from the cysteine residue of A2,
blocked access to the active site (5). Thus, the A-subunit in the
holotoxin was predicted to be enzymatically inactive. The A2
peptide includes the carboxyl-terminal tail, which in the three-
dimensional structure of Stx forms an -helix surrounded by
the five B-subunits. The carboxyl-terminal residues of A2 con-
tinue through the pore of the B-pentamer, but the last six
residues appeared to be disordered in the Stx structure. This
may result from the packing arrangement in the crystals, be-
cause two holotoxin molecules pack pentamer-to-pentamer,
and these six residues would be located at this interface.
Despite their similar sequences and expected similar struc-
tures, Stx1 and Stx2 cause different degrees and types of tissue
damage. If the E. coli O157:H7 with which a patient is infected
produces mainly Stx2, the patient is more likely to suffer from
hemolytic uremic syndrome than if the E. coli O157:H7 only
produces Stx1 (summarized by Siegler et al. (15)). The differ-
ence in pathogenicity between strains that produce only Stx2
and those that produce Stx1 alone or Stx1 and Stx2 was pos-
tulated to be due to the greater affinity of the Stx1 B-pentamer
for glycolipids (16). According to that theory, Stx1 would be
more likely to be picked up by intestinal epithelial cells, where
it could cause bloody diarrhea; Stx2 could then circulate
through the bloodstream to the kidneys where it would cause
the hemolytic uremic syndrome (17). However, both protein
toxins produce effects in animals that do not appear to be due
solely to targeting particular cell types (reviewed by
O’Loughlin and Robins-Browne (1)). The tissue damage may be
due to these other effects of the toxins and could be mediated by
residues of the holotoxin that are not involved in receptor
binding.
We have determined the structure of Stx2 and compared it
to that of Stx to contribute to the understanding of what
distinguishes Stx and Stx2 from each other. The experimen-
tal structures of the holotoxins can be used as templates upon
which to model anti-infective compounds to treat the diseases
caused by E. coli O157:H7 and other STECs. They can also be
used to design chimera that could be used to decipher the
different mechanisms of action of the two protein toxins in
animal models.
EXPERIMENTAL PROCEDURES
Expression, Purification, and Crystallization of Stx2—Stx2 was pro-
duced in E. coli DH5 using the pLPSH3 plasmid and purified by
immunoaffinity chromatography as previously described (13). The toxin
eluted from the column with 0.1 M glycine, pH 7.8, and was dialyzed in
TEAN (50 mM Tris, pH 7.5, with 1 mM EDTA, 3 mM sodium azide, and
0.2 M NaCl). SDS-PAGE analysis of the purified protein in the presence
of the reducing agent, 2-mercaptoethanol, showed that the A-subunit
was intact and had not been proteolyzed (data not shown).
Crystals of Stx2 were grown by vapor diffusion in hanging drops
using sodium formate as the major precipitant. The drops were formed
by mixing 1.5 l of a 9.4 mg/ml solution of the protein with 1.5 l of the
reservoir solution. The reservoir solution contained 4 M sodium formate,
0.1 M MES (pH 6.0), 50 mM 3-(1-pyridino)-1-propanesulfonate (PPS),
and 1% ethylene glycol. After a few days, crystals appeared as hexa-
gonal bipyramids. These were seeded into fresh solutions where they
grew to a maximum size of 0.35 mm by 0.30 mm within 3 weeks.
Structure Determination and Analysis—The crystals of Stx2 diffract
to better than 1.8-Å resolution. For the data collection, one crystal was
transferred to a solution containing 30% glycerol, 4 M sodium formate,
0.1 M MES (pH 6.0), and 1% ethylene glycol then vitrified at 100 K in the
nitrogen stream of a Molecular Structure Corp. low temperature device.
Diffraction data were collected from this crystal using a Raxis IV
image plate detector mounted on a Rigaku RU-H3R rotating anode
x-ray generator producing CuK radiation (  1.5418 Å) that was
monochromated and focused by Osmic mirrors. The data were pro-
cessed using the programs DENZO and SCALEPACK (18). From the
molecular weight, the unit cell dimensions, and the space group, the
crystals were predicted to contain one AB5-hexamer per asymmetric
unit.
The structure was solved by the molecular replacement method
using the programs ALMN (19) and BRUTE (20). The structure solution
was performed in two stages, finding first the orientation and position
TABLE II
Statistics for the crystallographic data of Stx2
Space group P61
Number of measurements 187,198
Number of unique reflections 66,898
Completeness (%) overall (1.86–1.80 Å) 98.3% (99.1%)
I/I overall (1.86–1.80 Å) 8.0 (2.8)
Rmerge
a overall (1.86–1.80 Å) 6.0% (25.2%)
a Rmerge  hkliI  I/hkli(I).
TABLE I
Sequence alignments of the A-subunits of Stx, Stx1, Stx2, ricin, and
the B-subunits of Stx or Stx1 and Stx2
The sequence alignments were generated using ClustalW (39). For
Stx, the sequence identifiers are CAA30741 and CAA30742 from Ref.
40; for Stx1 A, the sequence identifier is AAA98151 from Ref. 41; for
Stx2, the sequence identifiers are CAA30714 and CAA30715 from Ref.
42.
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of the B-pentamer in the asymmetric unit and, subsequently, the ori-
entation and location of the A-subunit. The search model for the B-
pentamer was the structure of a mutant form of Stx2e (8), identified as
2BOS in the Protein Data Bank (21). The rotation function for the
B-pentamer gave five peaks as expected, and the translation function
clearly showed that the space group was P61. The search model for the
FIG. 1. Electron density for Stx2.
The electron density from the 2 Fo  Fc,
c map is contoured at 1 near residues
forming the active site. The molecular
model is drawn as sticks, with water mol-
ecules depicted as filled circles. This fig-
ure was drawn with the programs BOB-
SCRIPT and MOLSCRIPT (35, 36).
FIG. 2. Ribbon diagram of Stx2. The A-subunit is red, whereas the B-subunits are orange (chain B), cyan (chain C), green (chain D), yellow
(chain E), and blue (chain F). The active site in the A-subunit is marked by the magenta letter A. The side chains of the cysteine residues that link
A1 and A2 are depicted in yellow. The sites equivalent to the Gb3-binding sites on the B-pentamer of Stx1 are shown by magenta numbers that
distinguish the type of binding site (6). This figure and Figs. 6 and 7 were drawn with the programs MOLSCRIPT and RASTER3D (35, 37).
TABLE III
Statistics for the refined model of Stx2 and for the refined model of Stx
Toxin type
Stx2 Stx
Resolution limit 1.77 Å 2.5 Å
Cell dimensions a  b  143.96 Å, a  133.00 Å
c  59.30 Å b  147.18 Å
    90°,   120° c  82.85 Å
      90°
Number of data for refinement 66,890 53,527
Completeness 97.6% 93.9%
R-factor (number of data) 15.1% (63,514) 19.9% (50,780)
R free (number of data) 18.4% (3,376) 25.7% (2,747)
Number of protein atoms 4,981 9,687
Number of water molecules 511 46
Number of atoms in ions or ligands 125 0
r.m.s. deviations from ideal geometry
Bond lengths (Å) 0.017 0.016
Bond angles (°) 2.0 1.9
Ramachandran plot
Number in most favored regions 522 (92.6%) 934 (85.8%)
Number in additional allowed regions 42 (7.4%) 147 (13.5%)
Number in generously allowed regions 0 6 (0.6%)
Number in disallowed regions 0 1 (0.1%)
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A-subunit was the A-subunit of Stx (5), using chain A of the structure
identified as 1DM0 in the Protein Data Bank (21). The model was
improved by cycles of maximum likelihood refinement using the Crys-
tallography and NMR System (22) and model building using the mo-
lecular graphics programs XFIT (23) and TOM/FRODO (24). The qual-
ity of the model was judged with information from the programs
PROCHECK (25) and WHATCHECK (26), and the final unit cell di-
mensions were those suggested by WHATCHECK.
The structure of Stx had been determined at lower resolution (2.5 Å)
(27) than that of Stx2 (1.77 Å), so we hypothesized that the model for
Stx could be improved by using information from the structure of Stx2.
As well, Stx had been refined prior to the use of the maximum likelihood
target in refinement (28). For these reasons, the Stx model was refined
for several additional cycles using the original data set (5). The final
refined structures of Stx and Stx2 were analyzed and compared using
programs from the CCP4 package (19) as well as the molecular graphics
programs O (29) and Swiss PDB Viewer (30). The atomic coordinates
and the structure factors for both Stx2 and Stx have been deposited in
the Protein Data Bank (21), where they have been assigned the iden-
tifiers 1R4P for Stx2 and 1R4Q for Stx.
RESULTS
Stx2—Table II presents the crystallographic details for Stx2,
and Table III presents the statistics from the refinement. This
is a well determined structure, as demonstrated by the low
values of the R-factors and the excellent geometry of the re-
fined model. The catalytic site of the A-subunit of Stx2 is
accessible in the crystal structure, and Fig. 1 shows that it
contains electron density. Three water molecules could be mod-
eled into this electron density, and their positions and temper-
ature factors were refined. The distances from these water
molecules to atoms of the protein were reasonable hydrogen
bonding distances, but the three were too close to each other for
hydrogen-bonding (2.0, 2.1, and 2.2 Å). Instead, for the final
model, a molecule of formic acid (used to crystallize the protein)
has been modeled in two alternate conformations to account for
the electron density. The crystal structure of Stx2 shows that
most of the A-subunit is located on one side of the B-pentamer,
but residues of A2 traverse the pore of the B-pentamer and
form a short helix on the cell surface binding side (see Fig. 2).
In the pore, residues of the A2 portion of Stx2 begin in an
-helical conformation (residues Ser-A278 to Leu-A285),
changing to an extended conformation from Asn-A286 to Ser-
A289. (The nomenclature indicates the amino acid residue fol-
lowed by the chain letter and the position of the amino acid
residue in that chain.) Ser-A289 initiates the final helix near
the carboxyl terminus of the A-subunit. This terminal helix
projects out of the B-pentamer pore at an angle of about 30° to
the base of the B-pentamer and packs alongside two of the
B-subunits. The final two residues of the A-subunit (Gly-A296
and Lys-A297) are not part of the helix, but they are well
ordered in the structure.
Stx—We next took the information from the structure of Stx2
and refined further the structure of Stx. The new refinement
improved the electron density in some regions, notably residues
43–46 and 184–188 of the A-subunit. Two and three additional
residues could be fit at the carboxyl termini of A1 and A2,
respectively, but the remaining carboxyl-terminal residues are
disordered in the crystal structure. Data for the newly refined
model for Stx are included in Table II.
DISCUSSION
Active Site of Stx2—The active site of the A subunit is acces-
sible in Stx2 in contrast to the active site of the A subunit in
Stx. In the crystal structure of Stx2, a molecule of formic acid
and a water molecule bound in the active site mimic the bind-
ing of adenine (Fig. 3). The water molecule interacting with
Arg-A170 closely approximates the position of N3 of adenine
when bound to ricin (31). The oxygen atoms of formic acid
occupy roughly the positions of N1 and N6 or N1 and N7 of the
adenine in the two alternate orientations of the molecule of
formic acid, and the carbon atom approximates the position of
C6 of adenine. The tyrosine residue (residue A77) that forms
part of the catalytic site is in a different conformation in Stx
FIG. 3. Active site of Stx2 (A) and ricin (B). Dashed lines repre-
sent hydrogen bonding interactions, and the interatomic distances are
noted. A, configuration of the two alternate conformations of formic acid
and a water molecule in the active site of Stx2. B, adenine bound to the
A chain of ricin (31). This figure was drawn using the program LIG-
PLOT (38).
FIG. 4. C trace of Stx2 superposed
on that of Stx. Stx2 is shown in solid
lines, whereas Stx is shown in dashed
lines in this stereoview. The superposi-
tion was based solely on structurally
equivalent residues of the B-pentamers.
This figure and Fig. 5 were drawn with
the program MOLSCRIPT (35).
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and Stx2, as well as in the structures of ricin alone and in ricin
when complexed with adenine. The different conformations of
the tyrosine residue in these active sites indicate that this
tyrosine side chain could adopt different conformations during
a catalytic cycle. The role of the tyrosine residue in catalysis is
most likely to bind the substrate by stacking with the adenine
FIG. 5. Active sites of Stx2 and Stx.
In this stereoview, residues of Stx2 are
drawn as gray stick models, whereas res-
idues of Stx are drawn in black. Specific
residues of Stx are labeled. The hydrogen
bonding interaction between the active
site tyrosine residue, Tyr-A77, and the
carbonyl oxygen atom of Pro-A258 is rep-
resented by a dashed line. Residues Ala-
257 to Ala-261 are the part of A2 that lies
across the active site.
FIG. 6. Receptor-binding sites 1 and 2. A, PPS and formic acid, drawn as gray stick models in this stereoview, bind to the site in Stx2 (cyan,
chain C) that is equivalent to the type 1 binding site for the Gb3 analogue (magenta) on the B-pentamer of Stx1 (green, chain B) (6). B, this
stereoview shows that the loop that binds the Gb3 analogue (magenta) at site 2 of the B-pentamer of Stx1 (green, chain F) has a different
conformation than the equivalent loop in Stx2 (blue, chain F) (6). Hydrogen bonding interactions in Stx2 are shown by dashed lines.
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ring. However, in the structure of Stx, this tyrosine residue
forms a hydrogen bond through its hydroxyl group with the
carbonyl oxygen atom of Pro-A258, one of the residues of A2. It
is this stretch of A2 that lies across the active site of Stx, as
shown in Fig. 4.
Superpositions of Stx2 and Stx—The orientation of the A-
subunit with respect to the B-pentamer differs in the two
holotoxins Stx2 and Stx. Fig. 5 shows the superposition of the
two holotoxins using only residues of the B-pentamers to align
the structures, which superpose with an r.m.s. deviation of 1.3
Å for the 340 C atoms. The A-subunits superpose with an
r.m.s. deviation of 0.84 Å for 246 C atoms. The sequences of
the A-subunits are most different in the region of the cleavage
loop and in the stretch of polypeptide following the second
cysteine residue. The B-subunits of Stx2 are two residues lon-
ger at the carboxyl terminus than the B-subunits of Stx; in both
toxins, the carboxyl-terminal residues of the B-subunits inter-
act with the A-subunit. These different specific interactions
may be responsible for the different orientations of the A-sub-
units with respect to their B-pentamers in the holotoxins.
Comparison of the Receptor-binding Sites—Three distinct
receptor-binding sites have been identified on the B-pentamer
of Stxs (6). Fig. 2 shows the locations of the equivalent sites on
Stx2.
Carbohydrate Binding Site 1—Receptor binding site 1 is
located in a groove formed by two B-subunits where they in-
teract to create the seven-stranded -sheet. A molecule of 3-(1-
pyridino)-1-propanesulfonate (PPS) is bound to Stx2 in four of
the five potential type 1 binding sites. Fig. 6A demonstrates
how the phenyl ring of PPS stacks against the indole ring of
Trp-C29, mimicking the binding of the second galactose ring of
the carbohydrate with the phenyl ring of Phe-30 of the B-
subunit of Stx1. In the fifth unoccupied type 1 binding site, the
side chain of Glu-A184 from a crystallographically related hex-
amer packs close enough to Trp-E29 to occlude the PPS-binding
site. Two of the type 1 binding sites that do bind PPS also
contain a molecule of formic acid that partially mimics the
binding of the first galactose ring of the carbohydrate. The
sulfonate group of each molecule of PPS also interacts with the
B-pentamer, primarily via a water molecule that forms a link to
Glu-15 of the B-subunit and to the side chain of Glu-64 of the
neighboring B-subunit. This interaction could be exploited in
the design of anti-infectives that would bind to site 1.
Carbohydrate Binding Site 2—The conformation of Stx2 at
the type 2 binding site differs from that of Stx, and the differ-
ences in both the sequences and the conformations are likely to
lead to the different binding affinities for Gb3. The first residue
of the B-subunit of Stx2 is alanine, which aligns with Pro-2 of
the B-subunit of Stx. The NH3
 group of Ala-1 forms a hydrogen
bond to the carbonyl oxygen atom of Ser-B53, leading to a
different conformation in the loop to which the carbohydrate
binds (Fig. 6B). The disulfide bond between cysteine residues
B3 and B56 of Stx2 adopts a conformation different from that of
the disulfide link between residues B4 and B57 of Stx1. For Gb3
to bind to Stx2 in the same way that the Gb3 analogue binds to
the B-pentamer of Stx1, there would have to be a change in the
conformation of this disulfide-bridged loop, otherwise the car-
bohydrate would clash with Ser-B54.
Carbohydrate Binding Site 3—The type 3 binding site is at
the base of the pentamer, where the tail of A2 emerges from the
B-pentamer pore in Stx2. The final two residues of A2 pack
against one of the tryptophan residues that have been shown to
be crucial for the binding of Gb3 at this lower affinity site (7,
32). In Stx2, the five tryptophan rings (residue 33 in each
B-subunit) all have clear electron density, but they do not adopt
a common conformation (Fig. 7A); whereas in the complex of a
Gb3 analogue with the B-pentamer of Stx1, all five tryptophan
side chains have similar conformations (Fig. 7B) (6). To bind
Gb3 at site 3, it may be necessary for all five binding sites to be
available, so that the tryptophan and the adjacent asparagine
FIG. 7. Receptor-binding site 3. A,
the tail of the A subunit (red) protrudes
from the base of the B-pentamer in Stx2,
as shown in this stereoview. The five
pairs of tryptophan and asparagine resi-
dues at the base of the B-pentamer
(shaded according to the chain identifier
as in Fig. 2) adopt different conforma-
tions. B, In the structure of the Gb3 ana-
logue bound to the B-pentamer of Stx, the
equivalent residues have similar confor-
mations for all five type 3 binding sites
(6).
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side chains are able to move in concert to the binding confor-
mation. This view is supported by the structure of a mutated
form of the Stx2e B-pentamer with the Gb3 analogue, in which
the carbohydrate is seen to bind to sites 1 and 2, but, surpris-
ingly, not to site 3 (8). In the crystals of this mutated Stx2e
B-pentamer in complex with the Gb3 analogue, an interaction
with a crystallographically related molecule causes one of the
tryptophan side chains to adopt a specific conformation that is
different from that in the complex of the B-pentamer of Stx1
with Gb3.
Roles for the Structural Differences in the Pathogenicity of
Stx2—Four major differences between the structures of Stx
and Stx2 were found in this study. First, the active site of Stx2
is accessible in the crystal structure, in contrast to the active
site of Stx that is blocked by part of the polypeptide chain of A2.
This greater accessibility of the Stx2 active site may contribute
to the apparently greater pathogenicity of Stx2 as compared
with Stx. It also means that inhibitors directed to the active
site of the N-glycosidase could bind to the Stx2 holotoxin in the
extracellular environment and enter the target cell in complex
with the holotoxin. Within the cell, these inhibitors would
prevent the toxin from shutting down protein synthesis. Sec-
ond, the carboxyl terminus of the Stx2 A-subunit forms a short
2-turn -helix after threading through the pore of the B-pen-
tamer, in contrast to the tail of the Stx A-subunit, which in the
crystals shows disorder in the same region. The carboxyl-ter-
minal tail of the Stx2d-activable A2 has been shown to be
involved in the enhanced toxicity of Stx2d-activable in the
presence of elastase from mucus (33, 34). Perhaps the more
ordered and extended structure found in the terminus of the
Stx2 A2, could, by analogy, also be found in Stx2d-activable,
and contribute to the accessibility of that peptide to elastase,
which cleaves the terminal two amino acids from the A2 car-
boxyl terminus (34). Third, one of the receptor binding sites in
the Stx2 B-pentamer has a different conformation than found
in the Stx B-pentamer, and that different conformation may
contribute to the different affinities of the two B-pentamers for
Gb3. Finally, the carboxyl terminus of the A1 peptide of Stx2
binds at one of the “receptor-binding” sites in Stx2, whereas
that site is unoccupied in Stx, a finding that, again, may par-
tially explain the different affinities of Stx and Stx2 for Gb3.
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